

Press Release

25 May 2026 14:30:00 CEST

Notice of annual general meeting in 2cureX AB

The shareholders of 2cureX AB, reg. no. 559128-0077 (the "Company"), are hereby invited to attend the annual general meeting on Thursday, 25 June 2026, at 10:00 a.m. at the premises of Forvis Mazars, Nordenskiöldsgatan 11A, SE-211 19 Malmö, Sweden.

Right to participate and notification

Shareholders wishing to attend the general meeting shall:

- be entered in the share register kept by Euroclear Sweden AB on Tuesday, 16 June 2026, and
- notify the Company no later than Thursday, 18 June 2026, by e-mail to ir@2curex.com. Notification may also be made in writing to 2cureX AB, c/o Talenom Consulting AB, Lilla Strandgatan 19, SE-261 31 Landskrona, Sweden. The notification shall state full name, personal or registration number, shareholding, address and daytime telephone number and should, where applicable, include information regarding any representative or assistants (no more than 2). Where applicable, the notification should be accompanied by powers of attorney, certificates of registration and other authority documents.

Nominee-registered shares

Shareholders whose shares are nominee-registered must, in order to be entitled to attend the annual general meeting, request through their nominee that the shares be temporarily registered in their own name in the share register kept by Euroclear Sweden AB as of the record date Tuesday, 16 June 2026 (so-called voting registration). Shareholders wishing to register the shares in their own name must, in accordance with each nominee's procedures, request that the nominee makes such voting registration. Voting registrations requested by shareholders in such time that the registration has been made by the relevant nominee no later than Thursday, 18 June 2026, will be taken into account in the preparation of the share register.

Proxies, etc.

If a shareholder is to be represented by a proxy, the proxy must bring a written, dated and signed power of attorney to the meeting. The power of attorney may not be older than one (1) year, unless a longer period of validity (no more than five (5) years) has been specified in the power of attorney. If the power of attorney is issued by a legal entity, the proxy must also bring a current certificate of registration or equivalent authority document for the legal entity. To facilitate access, a copy of the power of attorney and other authority documents should be attached to the notification of attendance. A proxy form is available on the Company's website www.2curex.com and will be sent by post to shareholders who contact the Company and provide their address.

Number of shares and votes

The total number of outstanding shares in the Company at the time of this notice is 31,902,916. The Company holds no own shares.

Proposed agenda:

1. Opening of the meeting.
2. Election of chair of the meeting.
3. Preparation and approval of voting list.
4. Election of one or two persons to verify the minutes.
5. Determination of whether the meeting has been duly convened.
6. Approval of the agenda.
7. Presentation of the annual report and the auditor's report.
8. Resolutions
 - a. on the adoption of the income statement and balance sheet;
 - b. on the disposition of the Company's profit or loss according to the adopted balance sheet; and
 - c. on the discharge from liability of the members of the board of directors and the CEO.
9. Determination of the number of board members and the number of auditors.
10. Determination of fees to the board of directors and the auditors.
11. Election of board of directors and auditors or auditing firm.
12. Resolution on amendment of the articles of association.
13. Resolution on authorisation for the board to resolve on issuance of shares.
14. Closing of the meeting.

Proposed resolutions in brief:

Resolution on the disposition of the Company's profit or loss according to the adopted balance sheet (item 8b)

The Board proposes that the annual general meeting dispose of the Company's profit or loss in accordance with the Board's proposal in the annual report.

The Board further proposes that no dividend be paid for the financial year 2025.

Determination of the number of board members and the number of auditors (item 9)

Shareholders of the Company have indicated that they propose that the board of directors shall consist of five (5) board members. The shareholders further propose that one (1) auditor be appointed.

Determination of fees to the board of directors and the auditor (item 10)

Shareholders of the Company have indicated that they propose that board fees be paid in the amount of 300,000 SEK to the chair of the board and 150,000 SEK to each of the other board members.

The shareholders have further proposed that auditor's fees be paid against approved invoice in accordance with customary billing standards.

Election of board of directors and auditors or auditing firm (item 11)

Shareholders of the Company have indicated that they propose the re-election of Ole Thastrup, Grith Hagel and Nathaniel Hutley and the election of Malgorzata Khrais and Jacob Scott as new ordinary board members. Tonni Bülow-Nielsen has declined re-election. For the position of chair of the board, the re-election of Ole Thastrup is proposed.

The Board has further proposed that the Company's auditor Martin Gustafsson be re-elected for the period until the end of the annual general meeting held in the next financial year.

Description of the new board members:

Malgorzata Khrais

Małgorzata Khrais is a business developer and commercial leader with over 15 years' experience across the life sciences sector, including biopharma, medical devices, advanced manufacturing and complex commercial transactions.

Małgorzata brings deep expertise in operational scaling, governance, quality systems and compliance within highly regulated environments, alongside a strong track record in supporting commercial growth and infrastructure development.

As a Board member of 2cureX AB, Małgorzata will support the advancement of the IndiTreat® functional precision oncology test into the British healthcare system, including the NHS. Drawing on her strong network within the UK life sciences ecosystem and her experience in healthcare innovation, she can help facilitate clinical partnerships, stakeholder engagement, and market access discussions aimed at demonstrating the value of functional precision medicine in improving treatment selection and patient outcomes within NHS oncology pathways.

Jacob Scott

Jacob Scott is a physician and clinical innovation leader with expertise spanning oncology, infectious disease, translational medicine, and evidence-based healthcare delivery in the United States. His work within multidisciplinary clinical and research environments has provided significant experience in precision medicine approaches and the integration of innovative diagnostics into oncology care pathways.

Jacob can play an important role in supporting the introduction and promotion of 2cureX AB's functional precision oncology offerings, including the IndiTreat® test, across the US market. Through collaboration with oncologists, hospital systems, and clinical research networks, he can help increase awareness of the clinical utility of functional precision testing in guiding treatment decisions, improving patient stratification, and advancing personalized cancer care across the US oncology landscape.

Resolution on amendment of the articles of association (item 12)

The Board proposes that the general meeting resolves to amend the company's articles of association in accordance with the following:

§ 4 Share capital and number of shares

Current wording

The share capital shall be no less than SEK 800,000 and no more than SEK 3,200,000. The number of shares shall be no less than 8,000,000 and no more than 32,000,000.

Proposed wording

The share capital shall be no less than SEK 3,190,291.60 and no more than SEK 12,761,166.40. The number of shares shall be no less than 31,902,916 and no more than 127,611,664.

Following the amendments, the articles of association shall have the wording set out in the complete proposed resolution.

A valid resolution requires the support of shareholders representing at least two-thirds of both the votes cast and the shares represented at the general meeting.

The Company's CEO shall be authorised to make such minor formal adjustments to the resolution as may prove necessary in connection with registration of the resolution with the Swedish Companies Registration Office (Bolagsverket).

Resolution on authorisation for the board to resolve on issuance of shares (item 13)

The board of directors proposes that the annual general meeting resolves to authorize the board of directors, during the period until the next annual general meeting, to resolve on the issuance of a maximum number of shares, convertibles and/or warrants entitling to subscription of, or entailing the issuance of, a maximum number of shares that can be accommodated within the limits of the articles of association, with or without deviation from the shareholders' preferential rights. The authorization may be exercised on one or several occasions and the board of directors shall be entitled to resolve on the detailed terms of issuance on each individual occasion. In addition to cash payment, payment may also be made with non-cash consideration or by way of set-off, or otherwise subject to conditions.

In order that the Company's current shareholders shall not be disadvantaged in relation to the outside investor(s) who may subscribe for shares in the Company, the board of directors deems it appropriate that issuance with deviation from the shareholders' preferential rights shall be made at a subscription price assessed by the board of directors as being on market terms, subject to a customary market discount where applicable.

A valid resolution requires the approval of shareholders representing at least two-thirds of both the votes cast and the shares represented at the annual general meeting.

Personal data

Personal data obtained from the share register kept by Euroclear Sweden AB, the notifications of attendance at the meeting and information regarding representatives, proxies and assistants will be used for registration, preparation of the voting list for the meeting and, where applicable, the minutes of the meeting.

Other

The annual report together with the auditor's report for the Company, as well as the complete proposed resolutions and proxy form, will be made available on the Company's website www.2curex.com and at the Company at the address 2cureX AB, Fruebjergvej 3, 2100 Copenhagen, Denmark, no later than three weeks before the annual general meeting, and will be sent to shareholders who so request and provide their postal address.

Shareholders attending the general meeting have the right to request information in accordance with Chapter 7, Section 32 of the Swedish Companies Act (2005:551).

Malmö in May 2026
2cureX AB
THE BOARD OF DIRECTORS

For more information about 2cureX:

Nathaniel Hutley, Interim CEO
E-mail: NH@2curex.com
Telephone: +44 (776) 514 1346

Kenneth Graabek Johansen, Chief Financial Officer
E-mail: KGJ@2curex.com
Telephone: +45 23 49 02 27

About 2cureX

2cureX is redefining cancer treatment selection through functional precision oncology. Its proprietary IndiTreat® test family creates thousands of 3D tumor replicas—called tumoroids—from a patient's biopsy to identify which chemotherapy or targeted drugs that are most effective for that specific tumor. The result: real data to drive real decisions.

The first three IndiTreat® tests target patients with metastatic colorectal cancer:

- IndiTreat® Start (first-line therapy)
- IndiTreat® Extend & Explore (third-line options)

New IndiTreat® versions are in development for earlier-stage colorectal cancer and other GI cancers. Despite global cancer IVD spending exceeding \$17.5 billion annually, fewer than 1 in 3 treatments are guided by a predictive test. IndiTreat® aims to close that gap—bringing clarity to treatment selection and precision to every patient.

2cureX AB is listed on Nasdaq First North Growth Market under the ticker 2CUREX, with operational delivery in partnership with 2cureX A/S in Denmark. This cross-border structure powers the company's new commercial strategy, Operation Twin Code—now live.

Certified Adviser

Redeye AB

This information is information that 2cureX is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-05-25 14:30 CEST.

Attachments

[Notice of annual general meeting in 2cureX AB](#)